share_log

The Three-year Underlying Earnings Growth at CK Life Sciences Int'l. (Holdings) (HKG:775) Is Promising, but the Shareholders Are Still in the Red Over That Time

The Three-year Underlying Earnings Growth at CK Life Sciences Int'l. (Holdings) (HKG:775) Is Promising, but the Shareholders Are Still in the Red Over That Time

CK Life Sciences Int'l的三年基础收益增长。(Holdings)(HKG: 775)前景看好,但在此期间股东仍处于亏损状态
Simply Wall St ·  02/01 17:05

You can invest in an index fund if you want to make sure your returns approximately match the overall market. But in any given year a good portion of stocks will fall short of that. Unfortunately for investors in CK Life Sciences Int'l., (Holdings) Inc. (HKG:775), the share price has slipped 39% in three years, falling short of the marketdecline of 32%. The more recent news is of little comfort, with the share price down 35% in a year. The falls have accelerated recently, with the share price down 25% in the last three months.

如果你想确保你的回报与整个市场大致相匹配,你可以投资指数基金。但是在任何一年中,很大一部分股票都将低于这个水平。不幸的是,对于长江生命科学国际(控股)有限公司(HKG: 775)的投资者来说,股价在三年内下跌了39%,低于32%的市场跌幅。最近的消息并不令人欣慰,股价在一年内下跌了35%。最近跌势加速,股价在过去三个月中下跌了25%。

Since CK Life Sciences Int'l. (Holdings) has shed HK$481m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

自从CK生命科学国际公司开始(Holdings)在过去7天中已从其价值下跌了4.81亿港元,让我们看看长期下跌是否是由该企业的经济推动的。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

不可否认,市场有时是有效的,但价格并不总是能反映潜在的业务表现。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。

Although the share price is down over three years, CK Life Sciences Int'l. (Holdings) actually managed to grow EPS by 1.9% per year in that time. Given the share price reaction, one might suspect that EPS is not a good guide to the business performance during the period (perhaps due to a one-off loss or gain). Or else the company was over-hyped in the past, and so its growth has disappointed.

尽管股价在三年内下跌,但CK生命科学国际。在那段时间里,(控股)实际上每年设法将每股收益增长1.9%。鉴于股价的反应,人们可能会怀疑每股收益并不能很好地指导该期间的业务表现(可能是由于一次性的亏损或收益)。否则,该公司过去曾被过度炒作,因此其增长令人失望。

After considering the numbers, we'd posit that the the market had higher expectations of EPS growth, three years back. However, taking a look at other business metrics might shed a bit more light on the share price action.

在考虑了这些数字之后,我们认为三年前市场对每股收益增长的预期更高。但是,查看其他业务指标可能会进一步了解股价走势。

With a rather small yield of just 1.5% we doubt that the stock's share price is based on its dividend. We note that, in three years, revenue has actually grown at a 3.3% annual rate, so that doesn't seem to be a reason to sell shares. This analysis is just perfunctory, but it might be worth researching CK Life Sciences Int'l. (Holdings) more closely, as sometimes stocks fall unfairly. This could present an opportunity.

由于收益率相当低,仅为1.5%,我们怀疑该股的股价是否基于其股息。我们注意到,在三年内,收入实际上以3.3%的年增长率增长,因此这似乎不是出售股票的理由。这种分析只是敷衍了事,但可能值得研究CK Life Sciences Int'l。(持股)更紧密,因为有时股票会不公平地下跌。这可能带来机会。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下图中看到收入和收入随时间推移而发生的变化(点击图表查看确切值)。

earnings-and-revenue-growth
SEHK:775 Earnings and Revenue Growth February 1st 2024
SEHK: 775 2024年2月1日的收益和收入增长

If you are thinking of buying or selling CK Life Sciences Int'l. (Holdings) stock, you should check out this FREE detailed report on its balance sheet.

如果你正在考虑买入或卖出CK Life Sciences Internat'l.(控股)股票,您应该在其资产负债表上查看这份免费的详细报告。

What About Dividends?

分红呢?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, CK Life Sciences Int'l. (Holdings)'s TSR for the last 3 years was -37%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence!

除了衡量股价回报率外,投资者还应考虑股东总回报率(TSR)。基于股息再投资的假设,股东总回报率纳入了任何分拆或贴现资本筹集的价值以及任何股息。因此,对于支付丰厚股息的公司来说,股东总回报率通常远高于股价回报率。碰巧的是,CK Life Sciences Internat'l。(Holdings)过去3年的股东总回报率为-37%,超过了前面提到的股价回报率。而且,猜测股息支付在很大程度上解释了这种分歧是没有好处的!

A Different Perspective

不同的视角

While the broader market lost about 20% in the twelve months, CK Life Sciences Int'l. (Holdings) shareholders did even worse, losing 35% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 6% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with CK Life Sciences Int'l. (Holdings) (at least 2 which make us uncomfortable) , and understanding them should be part of your investment process.

尽管整个市场在十二个月中下跌了约20%,但CK生命科学国际。(控股)股东的表现甚至更糟,亏损了35%(甚至包括股息)。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。好的一面是,长期股东赚了钱,在过去的五年中,每年增长6%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,投资风险的幽灵无处不在。我们已经向CK Life Sciences Internat'l确定了3个警告信号。(持股)(至少有2笔让我们感到不舒服),了解它们应该是您投资过程的一部分。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,请看一下我们预计收益将增加的这份免费公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Hong Kong exchanges.

请注意,本文引用的市场回报反映了目前在香港交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发